Table 1.
Baseline characteristics of the study population.
| Demographic variables | n = 73 (total) | n = 46 (DAT) | n = 27 (non-DAT) | p -value |
|---|---|---|---|---|
| Age, years | 65.7 ± 9.8 | 65.1 ± 9.6 | 66.7 ± 10.1 | 0.348 |
| Male, n (%) | 40 (54.8) | 28 (60.9) | 12 (44.4) | 0.173 |
| BMI, kg/m2 | 24.2 ± 2.7 | 24.7 ± 2.8 | 23.4 ± 2.2 | 0.079 |
| Type of AF | 0.562 | |||
| Persistent AF, n (%) | 24 (32.9) | 14 (30.4) | 10 (37.0) | |
| Paroxysmal AF, n (%) | 49 (67.1) | 32 (69.6) | 17 (63.0) | |
| Hypertension, n (%) | 44 (60.3) | 32 (69.6) | 12 (44.4) | 0.034* |
| Diabetes mellitus, n (%) | 8 (11.0) | 5 (10.9) | 3 (11.1) | 0.975 |
| Coronary artery disease, n (%) | 15 (20.5) | 10 (21.7) | 5 (18.5) | 0.742 |
| Congestive heart failure, n (%) | 9 (12.3) | 7 (15.2) | 2 (7.4) | 0.327 |
| Stroke/TIA, n (%) | 8 (11.0) | 6 (13.0) | 2 (7.4) | 0.457 |
| Baseline laboratory characteristics | ||||
| Hemoglobin, g/dl | 148.8 ± 13.3 | 149.1 ± 13.3 | 148.2 ± 13.7 | 0.805 |
| Platelet, 109/L | 219.3 ± 57.6 | 221.0 ± 58.5 | 216.3 ± 57.0 | 0.710 |
| White blood cell, 109/L | 5.6 ± 1.2 | 5.5 ± 1.1 | 5.6 ± 1.2 | 0.770 |
| eGFR, ml/min/1.73 m2 | 89.8 ± 13.9 | 89.7 ± 13.7 | 90.0 ± 14.4 | 0.846 |
| Echocardiographic parameters | ||||
| LAD, mm | 39.5 ± 5.8 | 39.8 ± 5.6 | 39.0 ± 6.3 | 0.432 |
| LVEDD, mm | 46.7 ± 4.4 | 47.2 ± 4.7 | 45.8 ± 3.8 | 0.213 |
| LVEF, % | 62.7 ± 6.2 | 63.2 ± 7.0 | 61.7 ± 4.5 | 0.121 |
| CHA2DS2-VASC score | 2.5 ± 1.7 | 2.5 ± 1.6 | 2.4 ± 1.9 | 0.589 |
| HAS-BLED score | 1.3 ± 0.9 | 1.3 ± 0.9 | 1.2 ± 0.8 | 0.734 |
| Preoperative anticoagulation therapy | ||||
| Warfarin, n (%) | 9 (12.3) | 7 (15.2) | 2 (7.4) | 0.327 |
| NOACs bridging with LMWH, n (%) | 41 (56.2) | 31 67.4) | 10 (37.0) | 0.012* |
| Uninterrupted dabigatran, n (%) | 23 (31.5) | 8 (17.4) | 15 (55.6) | 0.001* |
| Antiplatelet medications | ||||
| Aspirin, n (%) | 2 (2.7) | 2 (4.3) | 0 (0.0) | 0.272 |
| Clopidogrel, n (%) | 1 (1.4) | 1 (2.2) | 0 (0.0) | 0.440 |
Values are given as number (percent) or mean ± SD.
AF, atrial fibrillation; BMI, body mass index; eGFR, estimated glomerular filtration rate; LAD, left atrium diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LMWH, low-molecular-weight heparin; NOAC, non-vitamin K antagonist oral anticoagulant; TIA, transient ischemic attack.
*
p < 0.05.